PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2013 | 8 | 5 | 638-643
Tytuł artykułu

The percutaneous treatment of Patent Foramen Ovale, an effective and safe therapeutic choice

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Wydawca

Czasopismo
Rocznik
Tom
8
Numer
5
Strony
638-643
Opis fizyczny
Daty
wydano
2013-10-01
online
2013-09-18
Twórcy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy, rosa.trov@libero.it
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
autor
  • Cardiovascular Disease, Centre for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for Secondary Prevention — University of Palermo and Division of Cardiology — University Hospital “P. Giaccone”, Department of Internal Medicine and Cardiovascular Disease, Palermo, Italy
Bibliografia
  • [1] Schrader R. Indication and techniques of transcatheter closure of patent foramen ovale. J Interven Cardiol. 2003; 16:543–551 http://dx.doi.org/10.1046/j.1540-8183.2003.01054.x[Crossref]
  • [2] Homma S, Di Tullio MR, Patent foramen ovale and stroke. J Cardiol. 2010; 56:134–141 http://dx.doi.org/10.1016/j.jjcc.2010.05.008[Crossref]
  • [3] Overell JR, Bone I, and Lees KR, Interatrial septal abnormalities and stroke: A meta-analysis of casecontrol studies. Neurology. 2000; 55:1172–1179 http://dx.doi.org/10.1212/WNL.55.8.1172[Crossref]
  • [4] Fazio G, Ferro G, Barbaro G, Ferrara F, Novo G, Novo S. Patent foramen ovale and thromboembolic complications. Curr Pharm Des. 2010; 16:3497–3502 http://dx.doi.org/10.2174/138161210793563310[Crossref]
  • [5] Billinger M, Zbinden R, Mordasini R et al. Patent foramen ovale closure in recreational divers: effect on decompression illness and ischaemic brain lesions during long-term follow-up. Heart. 2011; 97:1932–1937 http://dx.doi.org/10.1136/heartjnl-2011-300436[WoS][Crossref]
  • [6] Reul J, Weis J, Jung A, Willmes K, Thron A. Central nervous system lesions and cervical disc herniations in amateur divers. Lancet. 1995; 345:1403–1405 http://dx.doi.org/10.1016/S0140-6736(95)92598-8[Crossref]
  • [7] Knauth M, Ries S, Pohimann S, et al. Cohort study of multiple brain lesions in sport divers: role of a patent foramen ovale. British medical journal. 1997; 314: 701–705 http://dx.doi.org/10.1136/bmj.314.7082.701[Crossref]
  • [8] Wilmshurst P, FRCP; Nightingale S, FRCP, The Role of Cardiac and Pulmonary Pathology in Migraine: A Hypothesis. Headache. 2006; 46:429–434 http://dx.doi.org/10.1111/j.1526-4610.2006.00374.x[Crossref]
  • [9] Cabanes, L. et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic ictus in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke. 1993; 24:1865–1873 http://dx.doi.org/10.1161/01.STR.24.12.1865[Crossref]
  • [10] Lechat, P. et al. Prevalence of patent foramen ovale in patients with ictus. N. Engl. J. Med. 1998; 318: 1148–1152 http://dx.doi.org/10.1056/NEJM198805053181802[Crossref]
  • [11] Webster, M. W. et al. Patent foramen ovale in young ictus patients. Lancet. 1988; 2:11–12 http://dx.doi.org/10.1016/S0140-6736(88)92944-3[Crossref]
  • [12] Job FP, Ringelstein EB, Grafen Y. Comparison of transcranial contrast Doppler sonography and transesophageal contrast echocardiography for the detection of patent foramen ovale in young ictus patients. Am. J. Cardiol. 1994; 74:381–384 http://dx.doi.org/10.1016/0002-9149(94)90407-3[Crossref]
  • [13] Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic ictus. Ann. Intern. Med. 1992; 117:461–465 http://dx.doi.org/10.7326/0003-4819-117-6-461[Crossref]
  • [14] Yeung M, Khan KA, Shuaib A. Transcranial Doppler ultrasonography in the detection of venous to arterial shunting in acute ictus and transient ischaemic attacks. J. Neurol. Neurosurg. Psychiatry. 1996; 61:445–449 http://dx.doi.org/10.1136/jnnp.61.5.445[Crossref]
  • [15] Handke M, Harloff A, Olschewski M, Hetzel A. Geibel A. Patent foramen ovale and cryptogenic ictus in older patients. N. Engl. J. Med. 2007; 357:2262–2268 http://dx.doi.org/10.1056/NEJMoa071422[Crossref]
  • [16] Windecker S, Meier B. Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale and cryptogenic stroke: to close or not to close? Closure: what else! Circulation. 2008; 118:1989–1998 http://dx.doi.org/10.1161/CIRCULATIONAHA.107.757013[Crossref]
  • [17] Messé SR, Kasner SE. Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale in cryptogenic stroke: not to close. Circulation. 2008;118: 1999–2004 http://dx.doi.org/10.1161/CIRCULATIONAHA.107.757021[Crossref]
  • [18] Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006; 37:577–617 http://dx.doi.org/10.1161/01.STR.0000199147.30016.74[WoS][Crossref]
  • [19] O’Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. A Call for Completion of Randomized Clinical Trials A Science Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke. AHA/ASA/Am. Coll. Circulation. 2009; 119:2743–2747 http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192272[Crossref]
  • [20] Heinisch C, Bertog S, Wunderlich N et al. Percutaneous closure of the patent foramen ovale using the HELEX® Septal Occluder: acute and long-term results in 405 patients. EuroIntervention. 2012; 8:717–723 http://dx.doi.org/10.4244/EIJV8I6A111[WoS][Crossref]
  • [21] Khairy P, O’Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003; 139:753–760 http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00010[Crossref]
  • [22] Windecker S, Wahl A, Nedeltchev K, Arnold M et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic ictus. J Am Coll Cardiol. 2004; 44:750–758 http://dx.doi.org/10.1016/j.jacc.2004.05.044[Crossref]
  • [23] Windecker, S. et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J. Am. Coll. Cardiol. 2004; 44:750–758 http://dx.doi.org/10.1016/j.jacc.2004.05.044[Crossref]
  • [24] Furlan, A J et al. Study design of the CLOSURE I trial. A prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the Starflex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke. 2010; 41:2872–2883 http://dx.doi.org/10.1161/STROKEAHA.110.593376[Crossref]
  • [25] Patrick A. Calvert, Bushra S. Rana, Anna C. Kydd & Leonard M. Shapiro. Patent foramen ovale: anatomy, outcomes, and closure. Nat Rev Cardiol. 2011; 8:148–160 http://dx.doi.org/10.1038/nrcardio.2010.224[WoS][Crossref]
  • [26] Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. NEngl J Med. 2001; 345:1740–1746 http://dx.doi.org/10.1056/NEJMoa011503[Crossref]
  • [27] Fazio G, Ferro G, Carità P, Lunetta M, Gullotti A, Trapani R, Fabbiano A, Novo G, Novo S. The PFO anatomy evaluation as possible tool to stratify the associated risks and the benefits arising from the closure. European Journal of Echocardiography. 2010; 11:488–491 http://dx.doi.org/10.1093/ejechocard/jeq003[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-013-0209-y
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.